admin – Page 6758 – Get News Story

From Family Legacy to Real Estate Success: Top Realtor in Sarasota, FL, Draws on Decades of Insight and Innovation

Sarasota, FL – In the heart of Sarasota’s bustling real estate scene, Jon Buice, an acclaimed Realtor in Sarasota, FL, has been making waves with a unique blend of familial wisdom and contemporary market strategies. Since rejoining the real estate industry in 2005, Buice has built a formidable reputation, drawing on a rich legacy of real estate expertise within his family and combining it with more than 25 years of management, marketing, and real estate experience.

“Rooted in a tradition of real estate excellence, I aim to elevate every client’s experience by blending time-honored practices with cutting-edge market insights,” says Jon Buice. This philosophy has not only distinguished him as a top real estate selling agent in Sarasota, Florida but also as a visionary who adapts to and anticipates market trends. Buice’s comprehensive approach to real estate, influenced by his family’s history in the industry and his own extensive background, ensures that his clients receive unparalleled service and results.

Buice’s expertise is further enhanced by his experience as both an appraiser and a realtor, offering a dual perspective that benefits clients across the board. Whether navigating the intricacies of the market for first-time homebuyers or strategizing investment opportunities for seasoned property investors, Buice’s insights are invaluable. His dedication to his clients and his craft sets him apart from other Realtors in Sarasota, Florida, making him a sought-after agent in the area.

Jon Buice’s journey from a family deeply entrenched in real estate to becoming an innovator in Sarasota’s competitive market exemplifies his commitment to excellence and client satisfaction. His unique blend of familial heritage and modern innovation ensures that every transaction is not just a success but a testament to his dedication to elevating the standard of real estate services.

For those looking to navigate the Sarasota real estate market, Jon Buice offers a partnership that promises not just results but a truly enhanced real estate experience. Visit https://www.floridassuncoasthomes.com/ to learn how Jon’s legacy of excellence and innovation can work for you, ensuring your real estate goals are met with expertise and genuine care.

Media Contact
Company Name: Jon Buice | Real Estate Agent in Sarasota FL
Contact Person: Jon Buice
Email: Send Email
Phone: +1 941-962-7443
Address:6941 Country Lakes Circle
City: Sarasota
State: Florida 34243
Country: United States
Website: https://www.floridassuncoasthomes.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: From Family Legacy to Real Estate Success: Top Realtor in Sarasota, FL, Draws on Decades of Insight and Innovation

Crohn’s Disease Pipeline Assessment 2024: Clinical Trials, FDA, EMA, PDMA Approvals, Therapies, Treatment Market, Mechanism of Action, Route of Administration by DelveInsight

“Crohn’s Disease Pipeline”

As per DelveInsight’s assessment, globally, Crohn’s Disease pipeline constitutes 70+ key companies continuously working towards developing 75+ Crohn’s Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

(New York, United States) Crohn’s Disease Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Crohn’s Disease Market.

The Crohn’s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report here @ Crohn’s Disease Pipeline Insight

Some of the key takeaways from the Crohn’s Disease Pipeline Report:

Crohn’s Disease Companies across the globe are diligently working toward developing novel Crohn’s Disease treatment therapies with a considerable amount of success over the years.
Crohn’s Disease companies working in the treatment market are Janssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo Biochem Inc., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Pfizer, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Pfizer, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Janssen, Roche, Eisai, Bristol-Myers Squibb, Iltoo Pharma, Suzhou Connect Biopharmaceuticals, Theravance Biopharma, TaiwanJ Pharmaceuticals, Celularity, Cerecor, GlaxoSmithKline, KangStem Biotech, Immunic, Alpha Cancer Technologies, Koutif Therapeutics, Tract Therapeutics, Trio medicines, ChemoCentryx, Algernon Pharmaceuticals, Neuclone, JHL Biotech, Innovative Pharmacological Research (IPHAR) Co Ltd, Innovation Pharmaceuticals, Exeliom Biosciences SAS, AbbVie, Finch Therapeutics, Akeso Biopharma, Draconis Pharma, MakScientific, Engitix, Origo Biopharma, Navidea Biopharmaceuticals, Orchard Therapeutics, Xbrane, Thetis Pharmaceuticals, Temisis Therapeutics, Synedgen, Synlogic, Morphic Therapeutic, Metacrine, Curacle, Commence Bio Inc, Cloud Pharmaceuticals, Chong Kun Dang Pharmaceutical Corp, Avobis Bio LLC, Avexegen Therapeutics, Assembly Biosciences, Aibios Co Ltd, Aclaris Therapeutics, Athos Therapeutics, Denali Therapeutics, Educell doo, and others, are developing therapies for the Crohn’s Disease treatment.
Emerging Crohn’s Disease therapies such as Guselkumab, ABP-654, RHB-104, Etrolizumab, PRA-023, AGMB-129, Filgotinib, Mirikizumab, Ozanimod, Brazikumab, Remestemcel-L, Rifaximin, Foralumab, ABX-464, Etrasimod, CYTO-201, Masitinib, HAV anti-MAP vaccine, Alequel, Cannabidiol, SHR0302, QBECO-SSI, PRV-6527, PF-06651600, MT-1303, TAK-018, SGX203, IMU 838, Alicaforsen, Bacteroides thetaiotaomicron, BT-11, JNJ-64304500, E6011, BMS-986165, Spesolimab, Aldesleukin, CBP-307, TD-1473, JKB-122, PDA-001, MDGN-002, GSK1070806, Furestem-CD, IMU-856, ACT-101, KT-1002, TregCel, TR8, CCX507, NP-178, NeuLara, JHL1255, Anti-inflammatory drug LIS, Brilacidin, Research programme: anti-fibrotic therapeutics Faecalibacterium Prausnitzii, Navitoclax, Research programme: Crohn’s disease therapeutics, AK 101, IBD Program, MAK 11049, GI restricted TGF-β inhibitor, Research programme: mannose receptor-targeted therapeutic agents, Research programme: haematopoietic stem cell based ex vivo gene therapy, Xcimzane, TP317, TEM1657, SYGN 313, SYNB 8802, MORF 057, IBD Program, CU06, MSC1 & MSC2, Phospholipid A2 (PLA2), CKD-506, Implantable cell therapies, Neuregulin-4 (NRG-4), ABBV-154, AIB-301, ATI-2138 ITK/TXK/JAK3 Inhibitor, JAK1/JAK3 Inhibitor, ITK/TXK/JAK3 Inhibitor, ATH-105, ATH-63, DNL975, CrohnArt, and others are expected to have a significant impact on the Crohn’s Disease market in the coming years.
On February 2024, Janssen Pharmaceutical announced a Phase 3, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Guselkumab in Participants with Moderately to Severely Active Crohn’s Disease.
On January 2024, AstraZeneca announced a Phase I, randomised, double-blind, placebo controlled study in healthy male and female subjects as well as patients with Crohn’s disease performed at a single study centre.

Crohn’s Disease Overview

Crohn’s disease is a chronic inflammatory bowel disease (IBD) characterized by inflammation of the gastrointestinal tract, commonly affecting the small intestine and colon. Symptoms include abdominal pain, diarrhea (sometimes bloody), fatigue, weight loss, and fever. The exact cause is unknown but likely involves a combination of genetic predisposition, immune system dysfunction, and environmental factors. Diagnosis relies on a combination of medical history, physical examination, blood tests, imaging studies (such as endoscopy and colonoscopy), and sometimes biopsy. Treatment aims to reduce inflammation, relieve symptoms, and prevent complications, and may include medications like corticosteroids, immunosuppressants, biologics, and dietary changes. In severe cases, surgery to remove damaged portions of the intestine may be necessary. Crohn’s disease is a lifelong condition with periods of flare-ups and remission, requiring ongoing management and monitoring by healthcare professionals.

Get a Free Sample PDF Report to know more about Crohn’s Disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/crohns-disease-cd-pipeline-insight

Crohn’s Disease Route of Administration

Crohn’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Crohn’s Disease Molecule Type

Crohn’s Disease Products have been categorized under various Molecule types, such as

Oligonucleotide
Peptide
Small molecule

Crohn’s Disease Pipeline Therapeutics Assessment

Crohn’s Disease Assessment by Product Type
Crohn’s Disease By Stage and Product Type
Crohn’s Disease Assessment by Route of Administration
Crohn’s Disease By Stage and Route of Administration
Crohn’s Disease Assessment by Molecule Type
Crohn’s Disease by Stage and Molecule Type

DelveInsight’s Crohn’s Disease Report covers around 75+ products under different phases of clinical development like-

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Crohn’s Disease product details are provided in the report. Download the Crohn’s Disease pipeline report to learn more about the emerging Crohn’s Disease therapies – https://www.delveinsight.com/sample-request/crohns-disease-cd-pipeline-insight

Crohn’s Disease Pipeline Analysis:

The Crohn’s Disease pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Crohn’s Disease with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Crohn’s Disease Treatment.
Crohn’s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Crohn’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Crohn’s Disease market.

Download Sample PDF Report to know more about Crohn’s Disease drugs and therapies- https://www.delveinsight.com/sample-request/crohns-disease-cd-pipeline-insight

Scope of Crohn’s Disease Pipeline Drug Insight

Coverage: Global
Key Crohn’s Disease Companies: Janssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo Biochem Inc., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Pfizer, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Pfizer, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Janssen, Roche, Eisai, Bristol-Myers Squibb, Iltoo Pharma, Suzhou Connect Biopharmaceuticals, Theravance Biopharma, TaiwanJ Pharmaceuticals, Celularity, Cerecor, GlaxoSmithKline, KangStem Biotech, Immunic, Alpha Cancer Technologies, Koutif Therapeutics, Tract Therapeutics, Trio medicines, ChemoCentryx, Algernon Pharmaceuticals, Neuclone, JHL Biotech, Innovative Pharmacological Research (IPHAR) Co Ltd, Innovation Pharmaceuticals, Exeliom Biosciences SAS, AbbVie, Finch Therapeutics, Akeso Biopharma, Draconis Pharma, MakScientific, Engitix, Origo Biopharma, Navidea Biopharmaceuticals, Orchard Therapeutics, Xbrane, Thetis Pharmaceuticals, Temisis Therapeutics, Synedgen, Synlogic, Morphic Therapeutic, Metacrine, Curacle, Commence Bio Inc, Cloud Pharmaceuticals, Chong Kun Dang Pharmaceutical Corp, Avobis Bio LLC, Avexegen Therapeutics, Assembly Biosciences, Aibios Co Ltd, Aclaris Therapeutics, Athos Therapeutics, Denali Therapeutics, Educell doo and others.
Key Crohn’s Disease Therapies: Guselkumab, ABP-654, RHB-104, Etrolizumab, PRA-023, AGMB-129, Filgotinib, Mirikizumab, Ozanimod, Brazikumab, Remestemcel-L, Rifaximin, Foralumab, ABX-464, Etrasimod, CYTO-201, Masitinib, HAV anti-MAP vaccine, Alequel, Cannabidiol, SHR0302, QBECO-SSI, PRV-6527, PF-06651600, MT-1303, TAK-018, SGX203, IMU 838, Alicaforsen, Bacteroides thetaiotaomicron, BT-11, JNJ-64304500, E6011, BMS-986165, Spesolimab, Aldesleukin, CBP-307, TD-1473, JKB-122, PDA-001, MDGN-002, GSK1070806, Furestem-CD, IMU-856, ACT-101, KT-1002, TregCel, TR8, CCX507, NP-178, NeuLara, JHL1255, Anti-inflammatory drug LIS, Brilacidin, Research programme: anti-fibrotic therapeutics Faecalibacterium Prausnitzii, Navitoclax, Research programme: Crohn’s disease therapeutics, AK 101, IBD Program, MAK 11049, GI restricted TGF-β inhibitor, Research programme: mannose receptor-targeted therapeutic agents, Research programme: haematopoietic stem cell based ex vivo gene therapy, Xcimzane, TP317, TEM1657, SYGN 313, SYNB 8802, MORF 057, IBD Program, CU06, MSC1 & MSC2, Phospholipid A2 (PLA2), CKD-506, Implantable cell therapies, Neuregulin-4 (NRG-4), ABBV-154, AIB-301, ATI-2138 ITK/TXK/JAK3 Inhibitor, JAK1/JAK3 Inhibitor, ITK/TXK/JAK3 Inhibitor, ATH-105, ATH-63, DNL975, CrohnArt, and others.
Crohn’s Disease Therapeutic Assessment: Crohn’s Disease current marketed and Crohn’s Disease emerging therapies
Crohn’s Disease Market Dynamics: Crohn’s Disease market drivers and Crohn’s Disease market barriers

Request for Sample PDF Report for Crohn’s Disease Pipeline Assessment and clinical trials – https://www.delveinsight.com/sample-request/crohns-disease-cd-pipeline-insight

Table of Contents

1. Crohn’s Disease Report Introduction

2. Crohn’s Disease Executive Summary

3. Crohn’s Disease Overview

4. Crohn’s Disease- Analytical Perspective In-depth Commercial Assessment

5. Crohn’s Disease Pipeline Therapeutics

6. Crohn’s Disease Late Stage Products (Phase II/III)

7. Crohn’s Disease Mid Stage Products (Phase II)

8. Crohn’s Disease Early Stage Products (Phase I)

9. Crohn’s Disease Preclinical Stage Products

10. Crohn’s Disease Therapeutics Assessment

11. Crohn’s Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Crohn’s Disease Companies

14. Crohn’s Disease Key Products

15. Crohn’s Disease Unmet Needs

16 . Crohn’s Disease Market Drivers and Barriers

17. Crohn’s Disease Future Perspectives and Conclusion

18. Crohn’s Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Crohn’s Disease Pipeline Assessment 2024: Clinical Trials, FDA, EMA, PDMA Approvals, Therapies, Treatment Market, Mechanism of Action, Route of Administration by DelveInsight

Pre-filled Syringes Market is expected to grow at a CAGR of 10.44%, estimates DelveInsight

“Pre-filled Syringes Market”

Prefilled Syringes companies are BD, NIPRO Pharma, Taisei Kako Co.,Ltd, TERUMO PHARMACEUTICAL SOLUTIONS., SCHOTT AG, Gerresheimer AG, West Pharmaceutical Services, Inc., Dali Medical Devices, Stevanato Group, Credence MedSystems, Inc., Baxter, MAEDA INDUSTRY Co., Ltd., MedXL Inc, IRISYS, LLC, Sandoz International GmbH, Pfizer Inc., Vetter, Weigao Group, Fresenius Kabi, Catalent Inc and others.

Global Prefilled Syringes Market was valued at USD 11.48 billion in 2021, growing at a CAGR of 10.44% during the forecast period from 2024 to 2030 to reach USD 20.83 billion by 2030. The demand for prefilled syringes is witnessing growth due to the growing prevalence of chronic diseases and autoimmune disorders such as diabetes and rheumatoid arthritis respectively, increasing popularity of biologic drugs, rising popularity of self-administration of drugs, offer a convenient alternative to conventional syringes and vials.

DelveInsight’s “Prefilled Syringes Market” research report provides the current and forecasted Prefilled Syringes Market trends for the next five years, upcoming innovations in the segment, and individual market shares, challenges, drivers & barriers, and key competitors in the market.

Request for a free sample report here @ Pre-filled Syringes Market

Recent developmental activities in Pre filled Syringes market

According to DelveInsight, the Prefilled Syringes Market was valued at USD 11.48 billion in 2021, growing at a CAGR of 10.44% during the forecast period from 2024 to 2030 to reach USD 20.83 billion by 2030.
Leading Prefilled Syringes companies working in the market are BD, NIPRO Pharma, Taisei Kako Co.,Ltd, TERUMO PHARMACEUTICAL SOLUTIONS., SCHOTT AG, Gerresheimer AG, West Pharmaceutical Services, Inc., Dali Medical Devices, Stevanato Group, Credence MedSystems, Inc., Baxter, MAEDA INDUSTRY Co., Ltd., MedXL Inc, IRISYS, LLC, Sandoz International GmbH, Pfizer Inc., Vetter, Weigao Group, Fresenius Kabi, Catalent Inc and others.
In July 2021, Fresenius Kabi launched ready-to-administer prefilled fentanyl syringe in the 1 ml volume format which is designed to cut waste and diversion by eliminating the possibilities of potential errors.
In May 2021, Glenmark Pharmaceuticals Limited received the US Food and Drug Administration approval for the Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe.
In April 2021, Roche received the approval from the US FDA for the supplemental Biologics License Application of the company for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.
In March 2021, Zealand Pharma announced the US FDA approval for the Zegalogue® (dasiglucagon) injection which is available in the prefilled syringe form, for the treatment of diabetes

For more insights into Pre filled Syringes Market, get the snapshot of the key highlights @ https://www.delveinsight.com/report-store/prefilled-syringes-market

Pre filled Syringes Overview

A prefilled syringe is a single-dose packet of vaccine to which a needle has been fixed by the manufacturer. In the past metal or glass syringes were popular, but increasingly there has been a movement towards plastic and disposable syringes so the needle is protected and cannot be reused (prefilled disposable systems). This has stimulated the demand for convenient and safe prefilled syringes.

Prefilled syringes have been around for more than two decades. Prefilled syringe manufacturers have had to therefore respond to increasing demand, new requirements and more sophisticated forms of drug delivery. There has been great development in syringes. New products are being put in syringes now. Prefilled syringes are used to package injectable drugs and diluents. Some of the categories of drugs packaged in prefilled syringes are vaccines, blood stimulants, therapeutic proteins, erythro proteins, interferon, and rheumatoid arthritis.

Interested in knowing how the Pre filled Syringes Market will be growing by 2030? Click to get a snapshot of Pre filled Syringes Analysis@ https://www.delveinsight.com/sample-request/prefilled-syringes-market

Geography Wise- Pre filled Syringes Market Analysis

The Blood Glucose Monitoring System market is analyzed geographically for North America, Europe, Asia-Pacific, and the Rest of the World. Among all the regions, North America is expected to account for the significant market share in the prefilled syringes market because of the high prevalence of autoimmune disorders, chronic diseases, rising population of the elderly as well as high awareness among people regarding disease management and the new product launches in the region.

The North American prefilled syringes market is witnessing an upward trend due to the rising prevalence of autoimmune diseases among other factors. In a study published in the journal Arthritis and Rheumatology by Dinse et al. in 2020, the researchers found that the prevalence of antinuclear antibodies (ANA), the most common biomarkers of autoimmunity, is increasing significantly in the United States in general, and more specifically in certain groups. Therefore, in order to cater to the medical needs of the large population suffering from autoimmune diseases such as RA, a number of medications are available in the prefilled syringes form. The well-established patient care system along with awareness among patients and caregivers regarding different types of prefilled syringes is further expected to propel the North American prefilled syringes market growth.

Pre filled Syringes Market Segmentation

By Product Design

Staked Needle System
Luer Cone System,
Luer Lock System

By Material

Glass
Polymer

By Usability

Reusable
Disposable

By End User

Hospitals & Clinics
Ambulatory Surgical Centers
Homecare Settings
and Others

By Geography

North America
Europe
Asia-Pacific
Rest of the World

Get a sneak peek at the Pre filled Syringes Market market dynamics @ https://www.delveinsight.com/sample-request/prefilled-syringes-market

Pre filled Syringes Market Segment Analysis

In the material segment of the prefilled syringes market, there is expected to be a shift from glass to polymer (plastic) syringes in the forecast period in order to overcome the shortcomings of the prefilled syringes made of glass. For instance, silicone oil (used to lubricate the inner surface of glass pre-filled syringe) is seen as a key factor which cannot be avoided in the manufacture of glass prefilled syringes yet is known to interfere with the properties of the biologics. Silicone is needed to ensure functionality, for components for prefilled syringes such as the plunger but silicone can alter sensitive proteins under certain conditions—causing them to aggregate or change their form. Therefore, polymer prefilled syringes are now being preferred over the glass prefilled syringes. The polymer prefilled syringes have high barrier properties against water vapor and oxygen, thereby effectively protecting the contents of the syringe. These syringes are also transparent, and are remarkably similar in appearance to glass syringes. This transparency also makes it easy to visually check content for haze, particles, and other imperfections. The Cyclo-Olefin-Polymer (COP) syringes are also much more resistant to breakage than their glass counterparts. Thus, the factors mentioned above are going to be instrumental in the increasing demand for plastic prefilled syringes in the forecast period.

Pre filled Syringes Market Scope

Study Period: 2020-2030
Key Pre filled Syringes Companies: BD, NIPRO Pharma, Taisei Kako Co.,Ltd, TERUMO PHARMACEUTICAL SOLUTIONS., SCHOTT AG, Gerresheimer AG, West Pharmaceutical Services, Inc., Dali Medical Devices, Stevanato Group, Credence MedSystems, Inc., Baxter, MAEDA INDUSTRY Co., Ltd., MedXL Inc, IRISYS, LLC, Sandoz International GmbH, Pfizer Inc., Vetter, Weigao Group, Fresenius Kabi, Catalent Inc and others.
Segmentation: By Product Design, By Material, By Usability, By End User, By Geography
Geography Covered: North America, Europe, Asia- Pacific, Rest of the World (Middle East, Africa, and South America)

Know more about which MedTech player is set to emerge as the trendsetter @ https://www.delveinsight.com/sample-request/prefilled-syringes-market

Table of Contents

Prefilled Syringes Market Report Introduction
Prefilled Syringes Market Executive Summary
Regulatory and Patent Analysis
Prefilled Syringes Market Key Factors Analysis
Prefilled Syringes Market Porter’s Five Forces Analysis
COVID-19 Impact Analysis on Prefilled Syringes Market
Prefilled Syringes Market Layout
Prefilled Syringes Market Global Company Share Analysis – Key 3-5 Companies
Prefilled Syringes Market Company and Product Profiles
Project Approach
KOL Views
DelveInsight Capabilities
Disclaimer
About DelveInsight

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pre-filled Syringes Market is expected to grow at a CAGR of 10.44%, estimates DelveInsight

Castle Rock, CO Realtor Wins Five Star Real Estate Agent Award for Sixth Consecutive Year

Cindy Rein, a well-known Realtor in Castle Rock, CO, has once again been honored with the prestigious Five Star Real Estate Agent Award, marking her sixth consecutive win from 2019 to 2024. This achievement is a testament to her unwavering commitment to excellence in the real estate industry and her dedication to providing top-tier service to her clients in the Castle Rock area.

Cindy’s recognition as a Five Star Real Estate Agent is complemented by her recent feature as the March 2024 Featured Agent in Top Agent Magazine. These honors highlight her status as a leading real estate agent in Castle Rock, CO, and underscore her expertise and success in a competitive market. Cindy’s ability to consistently win this award year after year showcases her proficiency in meeting and exceeding the needs of her clients.

In addition to these awards, Cindy is a Certified Negotiation Expert (CNE) and a Short Sale and Foreclosure Resource (SFR), and these certifications equip her with the necessary skills to handle complex transactions with professionalism and ease. Whether her clients are interested in buying or selling standard properties, navigating short sales and foreclosures, or exploring equestrian properties, Cindy offers a full-service experience that covers all aspects of real estate.

“Cindy’s dedication to her profession and her clients is what sets her apart,” said a spokesperson from her agency. “Her deep understanding of the local market, coupled with her negotiation expertise and specialized knowledge in areas like equestrian properties, allows her to serve a wide range of client needs.”

Those looking to buy or sell property with the help of the top real estate listing agent in Castle Rock, CO, are encouraged to reach out to Cindy Rein. Visit http://www.sherlockhomes.net/ to learn more about her services and how she can help you achieve your real estate goals. Contact Cindy today to experience the service and expertise that have earned her the Five Star Real Estate Agent Award for six years running. Whether you are buying your first home, seeking a unique property, or selling under challenging circumstances, Cindy is ready to ensure your real estate transactions are successful and smooth.

Media Contact
Company Name: Sherlock Homes | Real Estate Agent in Castle Rock CO
Contact Person: Cindy Rein
Email: Send Email
Phone: +1 720-272-4890
Address:880 W Happy Canyon Rd #120
City: Castle Rock
State: Colorado 80108
Country: United States
Website: http://www.sherlockhomes.net/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Castle Rock, CO Realtor Wins Five Star Real Estate Agent Award for Sixth Consecutive Year

Real Estate Agent in Lafayette, CA, Marks 3rd Year Of Exceptional Client Results

Omar Khan, a distinguished real estate agent in Lafayette, CA, is celebrating three years of significant achievement and client success in the highly competitive Lafayette real estate market. Since joining a top-producing team and transitioning to Vanguard Properties, Omar has continued to excel, demonstrating an innate ability to connect with and understand his clients’ diverse needs.

Omar’s approach to real estate is deeply influenced by his extensive background in hospitality and sales, which has honed his ability to engage with clients on a meaningful level. “Understanding and connecting with my clients is the cornerstone of my practice. It’s about more than houses; it’s about people and their dreams,” says Omar. This philosophy is propelling him to become one of the top Realtor agents in Lafayette, CA, known for his integrity, creativity, and relentless dedication to his clients.

2024 marks a year of continued growth for Omar, with an increase in personal business and client activity, reflecting his rising trajectory in the real estate industry. “This year has started with incredible momentum, and I am thrilled to continue providing top-tier real estate services to my clients,” Omar states, underscoring his commitment to excellence.

Omar’s success is also characterized by his unique blend of professional skills, combining his real estate knowledge with the relational expertise gained from his previous careers. As a real estate listing agent in Lafayette, CA, he is not only a negotiator and a marketer but also a trusted advisor and advocate for his clients. “Each client’s success is my success, and helping them achieve their real estate goals is what drives me every day,” he adds.

For those looking to navigate the dynamic Lafayette market, Omar Khan offers unparalleled expertise and a personalized approach to real estate. Visit https://kellycrawfordhomes.com/agents/omar-khan to learn more about how Omar can assist you with your real estate needs. Whether you are buying, selling, or simply exploring the market, Omar is the agent you can trust to guide you through the process with professionalism and care.

Media Contact
Company Name: Omar Khan, Realtor®
Contact Person: Omar Khan
Email: Send Email
Phone: +1 925-705-1609
Address:971 Dewing Ave
City: Lafayette
State: California 94549
Country: United States
Website: https://kellycrawfordhomes.com/agents/omar-khan

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Real Estate Agent in Lafayette, CA, Marks 3rd Year Of Exceptional Client Results

Image-Guided Surgery Devices Market is expected to grow exponentially at a CAGR of 5.81% by 2030, estimates DelveInsight

“Image-Guided Surgery Devices Market”

Image-Guided Surgery Devices companies include Koninklijke Philips N.V., Medtronic, Siemens Healthineers, General Electric Company, Varian Medical Systems, Inc., Brainlab AG, Quest Photonic Devices (Olympus), Stryker, Abbott, inomed Medizintechnik GmbH, Accuray Incorporated, medPhoton GmbH, 7D Surgical, OnLume Inc., IMRIS, Shimadzu Corporation, FUJIFILM Holdings, Nanjing Perlove Medical Equipment Co., Ltd., Allengers, Elekta AB, and others.

(New York, USA) DelveInsight’s “Image-Guided Surgery Devices Market” research report provides the current and forecasted Image-Guided Surgery Devices Market trends for the next five years, upcoming innovations in the segment, and individual market shares, challenges, drivers & barriers, and key competitors in the market.

Some facts of the Image-Guided Surgery Devices Market Report are:

The global Image-Guided Surgery Devices Market was valued at USD 5,540.87 million in 2021 and growing at a CAGR of 5.81% during the forecast period from 2023 to 2030, it is expected to reach USD 7,765.22 million by 2030.
Some of the key factors expected to drive the Image-Guided Surgery Devices Market include the rising burden of the geriatric population who are susceptible to developing various disorders, the increasing prevalence of chronic disorders, the growing number of product approvals, and technological advancements in the product arena, among others will contribute to the global Image-Guided Surgery Systems Market growth in the coming years.
The leading companies in the Image-Guided Surgery Devices Market include Koninklijke Philips N.V., Medtronic, Siemens Healthineers, General Electric Company, Varian Medical Systems, Inc., Brainlab AG, Quest Photonic Devices (Olympus), Stryker, Abbott, inomed Medizintechnik GmbH, Accuray Incorporated, medPhoton GmbH, 7D Surgical, OnLume Inc., IMRIS, Shimadzu Corporation, FUJIFILM Holdings, Nanjing Perlove Medical Equipment Co., Ltd., Allengers, Elekta AB, and others.

Interested in knowing how the Image-Guided Surgery Devices Market will be growing by 2030? Click to get a snapshot of the Image-Guided Surgery Devices Market Analysis.

Image-Guided Surgery Devices Overview

Image-Guided Surgery systems offer real-time monitoring during surgery, thereby helping healthcare professionals in reducing the procedure time and chances of errors. Image-Guided Surgery systems have revolutionized conventional surgical techniques by providing a precise treatment guidance system that can help ensure the safety of vital structures while maintaining the best outcome for patients. Various devices such as endoscopes, ultrasound, MRI, and others could be used for image-guided surgeries.

DelveInsight’s “Image-Guided Surgery Devices Market” provides an in-depth into the devices categorized by product type (ultrasound, endoscope, magnetic resonance imaging [MRI], computed tomography [CT], X-Ray fluoroscopy, others), by application (neurology, oncology surgery, ent surgery, orthopedic surgery, others), by end-user (hospitals, specialty clinics, and others), and by geography (North America, Europe, Asia-pacific, and rest of the world).

Computed tomography (CT), commonly referred to as a CT scan is a safe, quick imaging test to show layers of your body’s structures in great detail. A CT scan is a diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce images of the inside of the body including the bones, muscles, organs, and blood vessels. Fluorescence-guided technology is a lifesaving imaging technique that lights up tumors and cancer cells as well as nerves and other anatomical features in the body.

In the image-guided surgery devices product segment, the endoscopes segment is anticipated to hold a significant market during the forecast period. The rise in cases of gastrointestinal disorders, cancers, and renal disorders, among others, will also increase the demand for endoscope-guided surgery in the coming years.

Image-Guided Surgery Devices Market Analysis

Image-Guided Surgery Devices Market is expected to grow in the coming years owing to the increase in the prevalence and incidence of chronic disorders such as neurological disorders, cardiovascular disorders, and cancers, among others across the globe and the rise in the demand for image-guided surgery devices to improve surgical outcomes. The ongoing clinical trials by the research institutes for developing endoscopic imaging techniques for precise oncology treatment is another major factor expected to drive the Image-Guided Surgery Devices Market growth.

Additionally, the rising technological advancements such as higher resolution imaging, 3D imaging, and usage of robotics have allowed practitioners for carrying out more effective and accurate surgeries which reduces the length of hospitalization and also lowered the risk of revision surgeries is expected to contribute to the increasing demand for image-guided surgery systems.

Thus, the rising prevalence of diseases and increasing advancement in the existing image-guided surgery devices for improved surgical outcomes are anticipated to propel the image-guided surgery devices market in the coming years.

Interested to know more about the ongoing developments in the Global Image-Guided Surgery Devices Market? Visit to get an in-depth insight into Image-Guided Surgery Devices Types and Emerging Products

Image-Guided Surgery Devices – Global and Regional Market Assessment

As per DelveInsight, in terms of revenue share North America currently leads the global Image-Guided Surgery Devices Market and is projected to hold its leading position in the coming years as well. This domination is owing to the rapidly growing old age population in the region such as the US, in comparison to previous years which is also the key factor contributing to the rising market for Image-Guided Surgery Systems. As per the U.S. Census Bureau (2020), the 65-and-older population in the US grew by 3.2% (1,688,924) from 2018 to 2019. Also, as per the 2022 data revealed by the Government of Canada, approximately 7,081,792 persons were aged 65 years and above in Canada in the year 2021.

Further, the growth in the strategic business activities in the region such as company collaborations, acquisitions, product launches, and approval, among others are also expected to propel the market for image-guided surgery systems in the region.

Overall, the growth in the geriatric population in the region coupled with an increase in strategic business activities by the companies will greatly influence the regional Image-Guided Surgery Devices Market.

To know more about why North America is leading the market growth in the Image-Guided Surgery Devices market, get a snapshot of the report Image-Guided Surgery Devices market

Image-Guided Surgery Devices Market- Recent Breakthroughs & key Innovations

Over the years, the Image-Guided Surgery Devices Market has evolved immensely due to the active participation of the global MedTech companies and the technological advancements in the domain.

Here are a few of the major developments in the Image-Guided Surgery Devices Market-

In August 2021, Lightpoint Medical and Telix Pharmaceuticals entered into a strategic partnership agreement to explore the potential of integrating their technologies for radio-guided surgery (RGS) to spot cancer in real-time.
In December 2020, Philips collaborated with InSightec to expand access to MR-guided focused ultrasound for incision-less neurosurgery. Under this collaboration partnership, the companies are focused to develop compatibility between Philips’ advanced MR systems and the Exablate Neuro platform.
In December 2020, medPhoton GmbH received FDA approval for its Mobile ImagingRing System which is a robotic digital X-ray system enabling image-guided operations in medical fields such as general surgery, traumatology, and orthopedics, neurology, or radiotherapy.

Thus, owing to such developments in the market, there will be rapid growth in the Image-Guided Surgery Systems market during the forecast period.

Key Companies In the Image-Guided Surgery Devices Market

Some of the key market players operating in the Image-guided Surgery Devices market include Koninklijke Philips N.V. (NYSE: PHG), Medtronic (NYSE: MDT), Siemens Healthineers (OTCMKTS: SMMNY), General Electric Company (NYSE: GE), Varian Medical Systems, Inc., Brainlab AG, Quest Photonic Devices (Olympus), Stryker (NYSE: SYK), Abbott (NYSE: ABT), Inomed Medizintechnik GmbH, Accuray Incorporated (NASDAQ: ARAY), medPhoton GmbH, 7D Surgical, OnLume Inc., IMRIS, Shimadzu Corporation (TYO: 7701), FUJIFILM Holdings (OTCMKTS: FUJIY), Nanjing Perlove Medical Equipment Co., Ltd., Allengers, Elekta AB (OTCMKTS: EKTAY), and others.

As per DelveInsight, due to the very high growth rate and positive return, several new players are expected to enter the Image-Guided Surgery Devices Market in the coming years. The entry of new players and the launch of the emerging players will immensely drive the Image-Guided Surgery Devices Market growth.

Learn how new players’ entries will transform the Image-Guided Surgery Devices Market in the coming years @ Image-Guided Surgery Devices Competitive Landscape.

Covid-19 Impact on Image-Guided Surgery Devices Market

The COVID-19 pandemic has had a substantial effect on the image-guided surgery devices market. This is because surgery increases the risk of transmission of the infection as surgery involves cutting, abrading, and suturing which cannot be performed without coming in contact. Therefore, to avoid infection transmission patients avoided visiting hospitals. Also, stringent guidelines implemented by various governments across the globe, delays in various elective surgeries, and a halt in manufacturing facilities, among others have slowed down the market for image-guided surgery devices. However, the global launch of different vaccines and implementation of a mass vaccination drive is expected to normalize the market growth in the post-pandemic situation.

Image-Guided Surgery Devices Market Scope

Geography Covered: Global
Study Period: 2020-2030
By Product Type – Endoscopes, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Computed Tomography (CT) Systems, X-ray Fluoroscopy Systems, and other Product Types
By Application – Neurology, Orthopedic Surgery, Ear Nose Throat (ENT) Surgery, Oncology Surgery, and Other
By End-user – Hospitals, Specialty Clinics, and Others
By Geography – North America, Europe, Asia-Pacific, and Rest of World
Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Table of Contents

1. Report Introduction

2. Executive summary

3. Regulatory and Patent Analysis

4. Image-Guided Surgery Devices Market Key factors analysis

5. Image-Guided Surgery Devices Porter’s Five Forces Analysis

6. COVID-19 Impact Analysis on Image-Guided Surgery Devices Market

7. Image-Guided Surgery Devices Market Layout

8. Image-Guided Surgery Devices Global Company Share Analysis – Key 3-5 Companies

9. Image-Guided Surgery Devices Product Profiles and Key Companies

10. Project Approach

11. KOL Views

12. DelveInsight Capabilities

13. Disclaimer

14. About DelveInsight

Reach out to us to get a more detailed overview of the Image-Guided Surgery Devices Regulatory & Patent Analysis.

Key Takeaways From the Image-Guided Surgery Devices Market Report Study

In-depth analysis of the Image-Guided Surgery Devices Market size, share, and key trends.
Comprehensive analysis of current Image-Guided Surgery Devices Market size (2020) and market forecast for 5 years (2023-2030)
The effect of the COVID-19 pandemic on the Image-Guided Surgery Devices Market is significant. To capture and analyze suitable indicators, our experts are closely watching the Image-Guided Surgery Devices Market.
Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
Key companies dominating the Global Image-Guided Surgery Devices Market.
Various opportunities are available for the other competitors in the Image-Guided Surgery Devices Market space.
What are the top-performing segments in 2020? How these segments will perform in 2030.
Which are the top-performing regions and countries in the current Image-Guided Surgery Devices Market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for Image-Guided Surgery Devices Market growth in the coming future?

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Image-Guided Surgery Devices Market is expected to grow exponentially at a CAGR of 5.81% by 2030, estimates DelveInsight

Harnessing AR in Logistics: Vuzix’s (NASDAQ: VUZI) Smart Glasses Revolutionize Warehouse Operations

AR related sector stocks: Vuzix Corporation (NASDAQ: VUZI), MicroVision Inc (NASDAQ:MVIS), Immersion Corporation (NASDAQ:IMMR), Enovix Corp (NASDAQ:ENVX), Snap Inc (NYSE:SNAP), Unity Software Inc (NYSE:U), Sony Group Corporation (NYSE:SONY), Roblox Corp (NYSE:RBLX), PTC Inc (NASDAQ:PTC), Autodesk Inc (NASDAQ:ADSK), Texas Instruments Inc (NASDAQ:TXN), QUALCOMM Inc (NASDAQ:QCOM), Advanced Micro Devices Inc. (NASDAQ:AMD), Adobe Inc (NASDAQ:ADBE), Apple Inc (NASDAQ:AAPL).

In the rapidly evolving world of logistics, augmented reality (AR) is proving to be a game-changer. Vuzix® Corporation (NASDAQ: VUZI), a pioneer in smart glasses and AR technology, recently spotlighted a significant leap forward in logistics efficiency with its Vuzix M400™ smart glasses, as detailed in a successful collaboration with Nadro S.A. de C.V., Mexico’s leading pharmaceutical distributor. This development underscores not only the practical applications of AR in complex environments but also its potential for substantial investment returns.

Revolutionizing Warehouse Operations with Vuzix Smart Glasses

Nadro, challenged by global supply chain disruptions, skills shortages, and surging demand, turned to AR to streamline operations. Implementing TeamViewer Frontline’s vision picking solution on Vuzix’s M400 smart glasses, Nadro has seen a 30% improvement in picking times and a staggering 93% reduction in training and onboarding times. This technological integration has enabled Nadro to dispatch 51 million medical and personal care products monthly across Mexico more efficiently than ever before.

The Vuzix M400 smart glasses facilitate a digitalized, cloud-based picking process that reduces the need for manual input and allows for quicker adaptation by new employees, significantly reducing overhead costs and eliminating overtime. This enhancement in operational efficiency not only boosts productivity but also improves employees’ work-life balance, demonstrating Vuziz’s commitment to technology that serves human as well as corporate needs.

Strategic Expansion and Future Potential

Nadro’s plan to triple the number of AR-equipped warehouse personnel in 2024 indicates a strategic commitment to expanding this technology’s role across its operations. This expansion is not just a testament to the success of the initial implementation but also reflects the broader potential for AR in logistics beyond traditional picking activities.

For investors, this represents a compelling point of interest. Vuziz’s strategy of partnering with software giants like TeamViewer and local support from Acuraflow suggests a robust business model that maximizes the reach and effectiveness of their hardware solutions. The scalability of this technology could serve as a significant growth vector in other sectors requiring logistical support under similar strains.

Investment Implications

Vuzix stands out in the AR market not only for its innovative technology but also for its strategic market positioning. Holding over 375 patents, Vuzix is well-protected in its technological advancements and poised for continued innovation and market expansion. With a history of recognition at CES and various other technology innovation awards, Vuziz’s credibility and industry standing make it a noteworthy candidate for investor consideration.

The company’s ability to deliver real-world solutions that provide significant ROI is evident in its ongoing success with Nadro. This success story not only highlights the efficacy of Vuzix’s products but also illustrates the growing necessity and efficiency of AR solutions in modern enterprises.

As Vuzix continues to develop and market cutting-edge AR technologies, its impact on industries such as logistics, medical, defense, and consumer markets is becoming increasingly clear. For traders and investors, Vuzix represents a unique opportunity to invest in a technology that is not just creating waves but shaping the future of how businesses manage logistics and operations in an increasingly digital world.

By capitalizing on the transformative potential of AR glasses like those developed by Vuzix, businesses can dramatically enhance operational efficiency and scalability. For savvy investors, keeping an eye on companies like Vuzix, which are at the forefront of such innovative solutions, could be particularly rewarding.

Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or an endorsement of ATNM or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at https://investorbrandmedia.com/disclaimer/. InvestorBrandMedia.com has been compensated one thousand and five hundred dollars by a 3rd party Bullzeyemedia LLC for content distribution services on VUZI for April 22th to April 25th, 2024. We own zero shares of VUZI. InvestorBrandMedia.com is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of InvestorBrandMedia.com is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future results.InvestorBrandMedia.com does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at https://www.sec.gov/edgar/searchedgar/companysearch. It is always important to conduct thorough due diligence and exercise caution in trading.InvestorBrandMedia.com is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by InvestorBrandMedia.com or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. InvestorBrandMedia.com is not a fiduciary by virtue of any person’s use of or access to this content.

Media Contact
Company Name: Investor Brand Media
Contact Person: Ash K
Email: investorbrandmedia@gmail.com
Phone: (954) 593-5597
Country: United States
Website: https://investorbrandmedia.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Harnessing AR in Logistics: Vuzix\’s (NASDAQ: VUZI) Smart Glasses Revolutionize Warehouse Operations

4 Stocks To Watch In The $1.8 Trillion Race To Net Zero (VVPR, LI, SOL, FREY)

Cutting down emissions to net zero is one of the world’s most ambitious goals, thanks to the Paris climate agreement. That goal is being taken so seriously that BloombergNEF recently reported that the amount invested in the green energy transition will reach a staggering $1.8 trillion in 2023.

But for the world to achieve net zero status, shifting our transportation’s reliance from internal combustion engines to electrical vehicles will have to be accelerated. Last year, global sales of EVs, including BEVs, PHEVs (Plug-in Hybrid Electric Vehicles), and FCVs (Fuel Cell Vehicles), reached 13 million units in 2023, representing a 29.8% growth compared to 2022.

At the same time, the world put $634 billion toward electric vehicles and charging technology in 2023, or 85% of its total investment in clean technologies that consume energy, according to BloombergNEF, which drew more spending than renewables for the first time.

Over the past couple of months, the electric vehicle (EV) sector has been going through turbulent times against the backdrop of macroeconomic headwinds and intense competition. This has caused the markets to overreact to the downside, creating opportunities for buying EV stocks at a valuation gap.

In our view, even the slightest of positives could translate into a significant rally from oversold levels for EV stocks. And it’s not only pure EV makers that will benefit from this trend but also the picks and shovels of the industry, like battery makers. Here are four stocks to add to your watchlist.

VivoPower International (NASDAQ:VVPR) is a sustainable energy solutions company that has recently been making headlines in the EV space.

Through its subsidiary Tembo e-LV, vivopower develops and distributes conversion kits with all the parts required to convert a vehicle from an internal combustion engine to an EV. These include the motors, batteries, transmission, charger, software, and the rest of the components that make the converted vehicle work.

Tembo’s value proposition here is that users will incur lower maintenance and operational costs, less downtime, and won’t have the need for expensive fuel infrastructure.

This unique approach to electrifying vehicles has shown massive potential since it’s much more cost-effective than outright buying a new one. To better illustrate this, VivoPower International (NASDAQ:VVPR) recently secured an order commitment of more than 5000 kits (1,000 for Jordan and 4,000 for Kenya) and an order pipeline of another 10,000+ kits.

What’s most exciting about these orders is that they could be just the tip of the iceberg. Jordan offers the perfect entry point to the Middle East EV market, which experts project will grow at a CAGR of about 28.9% till 2030. The Middle East is also the world’s largest landcruiser market, which is perfectly suited for Tembo’s conversion kits. On the other hand, Kenya provides VivoPower with the means to establish a foothold in the second-hand vehicle conversion market, which some estimate has a value of about $2 billion.

Although VivoPower International’s (NASDAQ:VVPR) entry into the EV market has already rewarded a number of early shareholders with triple-digit returns, the stock appears to still have room for further upside based on a number of catalysts.

For starters, the company recently announced that Tembo would go public via a merger with Cactus Acquisition Corp. 1 Limited (CCTS), a NASDAQ-listed SPAC, and change its name to Tembo Group. According to the details of the transaction, CCTS will issue 83.8 million shares at $10 per CCTS share in exchange for Tembo shares, which implies a valuation of $838 million. In addition to that, a bonus of 16.76 million Tembo Dividend Shares will be distributed to VivoPower shareholders, who will receive 5 Tembo Group shares for each VivoPower share held.

Assuming a conservative IPO price of just $1 per Tembo share instead of $10, it would mean that VivoPower International (NASDAQ:VVPR) shares are worth at least $28 each.

While that potential upside may appear too good to be true, it is further supported by the fact that Vivopower received a direct investment of $5 million into Tembo at a pre-money valuation of $120 million from a private investment office of a member of the ruling Al Maktoum family of Dubai. For context, Vivopower currently has a market cap of just $12 million.

That investment not only reaffirms investor interest in the Middle East and Africa’s EV market but also in vivopower’s long-term growth prospects. Furthermore, the company recently announced that executive chairman and CEO Kevin Chin increased his individual shareholding in the company by 146,084 shares (about 4.4% of the outstanding shares) to increase his shareholding to 12.3%.

Going forward, VivoPower International (NASDAQ:VVPR) will build on its initial success in the Middle East and Africa to continue its Asia expansion after signing a definitive joint venture agreement with Francisco Motor Corporation to develop and supply electric utility vehicle electrification kits for a new generation of electric jeepneys (e-jeepneys) in the Philippines.

Li Auto (NASDAQ:LI) designs, develops, manufactures, and sells premium smart electric vehicles. The China-based EV maker has clearly been the strongest performer recently in the lackluster EV space. Li Auto remains by far the fastest-growing, well-established EV maker out there.

The company recently launched the Li L6, a five-seat premium family SUV that will offer Pro and Max trims in spite of the recent weakness in the market, signaling that the long-term fundamentals still remain strong.

In the meantime, however, Li Auto has resorted to price cuts to deal with the softening demand. The car maker announced price cuts for four out of the five models it produces. We’re talking about roughly 5% of the existing sale price, or about $4,100 off of what it’s selling for right now.

The price cuts came as new data showed that, for the first time, China sold more electric and hybrid cars than internal-combustion vehicles. Retail sales of new-energy cars, which include EVs and plug-in hybrids, made up 50.4% of all passenger-vehicle sales in the first two weeks of April, according to data from the China Passenger Car Association.

Li recently reported full-year 2023 earnings, where revenue grew an impressive 173.5% year-over-year to reach $17.2 billion. The company is projected to deliver 57% top-line growth in 2024, with consensus estimates calling for $27 billion in sales this year. Citigroup maintains a buy rating on Li Auto stock with a $43.60 price target.

Emeren Group Ltd. (NYSE:SOL) is a renewable energy leader with a comprehensive portfolio of solar projects and independent power producer (IPP) assets, complemented by a significant global battery energy storage system (BESS) capacity.

The company recently announced a number of milestones, including that it had signed a co-development agreement for 199 MW (up to 1.59 GWh of capacity) of battery storage projects in two regions of southern Italy with Nuveen Infrastructure, one of the world’s largest fund managers investing in clean energy. This agreement marks the final stage in the portfolio collaboration between Emeren and Nuveen, achieving a total power capacity of 354 MWp (up to 2.83 GWh).

SOL also announced that it had set up a 703 megawatt BESS project portfolio in Italy for Matrix Renewables under the Development Service Agreement, or DSA, which, combined with the previous sale of the 260 megawatt in Q2, amounted to a total of 963 megawatts of BESS projects. This marked a substantial advance towards the agreed portfolio target of 1.5 gigawatts in the DSA partnership with Matrix.

The company also announced the expansion of its energy storage portfolio in China by acquiring a 10.8 megawatt-hour energy storage portfolio comprising six energy storage power stations. According to its most recent filings, SOL closed FY 2023 with $104.7 million in revenue, a 22.2% gross margin, and a $9.3 million net loss. These results were below our full-year guidance, primarily due to the delays in closing the sales of six projects in the US and Europe.

FREYR Battery, Inc. (NYSE:FREY) develops clean, next-generation battery cell production capacity with a focus on the primary markets of energy storage systems (“ESS”) and commercial mobility.

Last month, FREYR’s team at its Customer Qualification Plant (“CQP”) reached a key milestone by producing automatically casted electrodes with active electrolyte slurry in a dry room environment, and the company expects to make functional battery cells for customer samples using full automation of CQP in H1 2024.

A key distinction between FREY’s production platform and conventional lithium-ion battery manufacturing technology is the order in which electrolyte is introduced to the process. In the 24M process, electrolyte is added at the start of cell processing, which eliminates the costly and energy-intensive step of solvent recovery by drying the electrodes.

That milestone follows another key achievement by the company, which announced that the U.S. Department of Energy (DOE) had invited the company to submit the Part II loan application under the DOE Title 17 program for FREYR’s Giga America project.

“The Part II DOE loan application invitation is an important next step in FREYR’s journey to fund our Giga America project,” commented Birger Steen, FREYR’s Chief Executive Officer. “With our redomiciliation to the U.S. now approved by our shareholders, FREYR is uniquely positioned to establish the Company as the U.S.-based industrialization partner of choice for clean battery technology solutions.”

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, or assumptions of future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. Capital Gains Report (CGR) owned by RazorPitch Inc. is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. CGR has been retained by VivoPower International PLC. to produce and distribute content related to VVPR. As part of that content, readers, subscribers, and webs are expected to read the full disclaimers and financial disclosure statement that can be found on our website https://capitalgainsreport.com. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: Capital Gains Report
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: FLORIDA
Country: United States
Website: https://capitalgainsreport.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: 4 Stocks To Watch In The $1.8 Trillion Race To Net Zero (VVPR, LI, SOL, FREY)

Lake Anna Asphalt Solutions Outlines Different Drainage Techniques Used During Asphalt Paving

Lake Anna Asphalt Solutions is a premier paving company. In a recent update, the company outlined different drainage techniques used during asphalt paving.

Mineral, VA – In a website post, Lake Anna Asphalt Solutions outlined different drainage techniques used during asphalt paving.

The paving contractor Mineral noted that one of the most common drainage techniques used during asphalt paving is known as surface drainage. This technique involves creating a slope or grade on the surface of the pavement to direct water away from the paved surface. This can be accomplished by using specialized machinery, such as a motor grader, to shape the surface of the asphalt.

The technicians said that another drainage technique utilized in asphalt paving Mineral is known as sub-surface drainage. In this method, perforated pipes are installed under the paved surface to collect and redirect excess water. These pipes are connected to a drainage system, such as a storm drain, which carries the water away from the paved area. It can also be an effective solution for preventing water from seeping into the base of the pavement.

The asphalt contractor Mineral asserted that permeable paving is a newer drainage technique that has gained popularity in recent years. This method involves using porous materials, such as gravel or open-cell pavers, as the base layer of the pavement. These materials allow water to pass through them and into the underlying soil, reducing the amount of water that collects on the surface. Permeable paving is not only effective for drainage, but it also helps to reduce runoff and improve water quality.

About Lake Anna Asphalt Solutions

Lake Anna Asphalt Solutions is a top-rated paving company. They offer various services, including asphalt paving, repairs, seal coating, crack sealing, and line striping. The skilled crew works efficiently and effectively to ensure a smooth and seamless process. They also use only the highest-quality materials, ensuring long-lasting and durable results for their clients.

Media Contact
Company Name: Lake Anna Asphalt Solutions
Contact Person: Courtney Nelson
Email: Send Email
Phone: (540) 306-4698
Address:967 Haley Dr
City: Mineral
State: VA
Country: United States
Website: https://www.lakeannaasphaltpaving.com/asphalt-paving-contractor-lake-anna-va/

Quality and Durable Asphalt Paving Services that Improve Property Look

Asphalt paving for residential and commercial spaces like driveways, roads, and parking lots improves the space’s look. Asphalt comes easily maintained when properly installed by an expert asphalt contractor. Numerous asphalt contractors are in the company, and working with the right one increases the chances of getting an excellent result.

Jacksonville, NC – Jacksonville Family Paving is a fully licensed and skilled asphalt resurfacing company Jacksonville that has several years of experience in asphalt service provision. The asphalt professionals know and guarantee the delivery of an asphalt service that meets the needs of residential and commercial clients. The company crew has the skills and equipment to deliver excellent service regardless of the project size.

Clients look for the most cost-effective solution for their properties, which Jacksonville Family Paving helps them achieve. The asphalt repair Jacksonville provides a no-obligation estimate on all their services, whether for an installation, repair, or seal coating project. Also, clients receive a free quote on the desired service, making their services more affordable.

Jacksonville Family Paving professionals provide high-quality materials and artistry, which helps achieve durability. Additionally, their skilled driveway paving, Jacksonville, has experience handling different kinds of services such that the residential or commercial building gets an improved curb appeal that makes it stand out.

Jacksonville Family Paving has skilled contractors who guide homeowners who seek to change the shape of their current driveway. The professionals visit the client’s home and guide them accordingly for the best option, depending on their needs and the property size.

About Us

Jacksonville Family Paving is a professional and reliable asphalt company with numerous years of experience. Call today!

Media Contact
Company Name: Jacksonville Family Paving
Contact Person: Brett Lynch
Email: Send Email
Phone: (910) 812-8130
Address:State Rd 1702 #E
City: Jacksonville
State: NC
Country: United States
Website: https://jacksonvillencpavingpros.com/paving-contractor-jacksonville/